Morgan Stanley Reiterates CHF 290 Price Target for Roche Holding Ltd. (ROG)

Evrard Martin
Juin 20, 2017

Zurich Insurance Group AG (VTX:ZURN) received a CHF 295 price objective from investment analysts at Morgan Stanley in a research note issued on Saturday, May 20th. The firm now has a sell rating on the stock.

COPYRIGHT VIOLATION NOTICE: "J P Morgan Chase & Co Reiterates Buy Rating for Roche Holding Ltd. (ROG)" was first published by Chaffey Breeze and is the property of of Chaffey Breeze. Goldman Sachs Group, Inc.

Separately, J P Morgan Chase & Co set a CHF 302 target price on shares of Zurich Insurance Group AG and gave the company a "neutral" rating in a research report on Saturday, May 20th. The stock presently has an average rating of "Hold" and an average price target of CHF 292.83. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the stock. The company now has a consensus rating of Hold and an average target price of CHF 78.

Shares of Novartis AG (VTX NOVN) opened at 79.90 on Friday. The firm's 50-day moving average is CHK 78.71 and its 200 day moving average is CHK 75.22. The stock has a market capitalization of CHK 215.46 billion and a price-to-earnings ratio of 22.24. Zurich Insurance Group AG has a 52-week low of CHK 218.70 and a 52-week high of CHK 292.40. If you are reading this news story on another site, it was stolen and reposted in violation of United States and worldwide copyright and trademark laws. The original version of this piece can be accessed at https://www.chaffeybreeze.com/2017/06/19/roche-holding-ltd-rog-receives-buy-rating-from-jpmorgan-chase-co-updated-updated-updated-updated.html.

Zurich Insurance Group AG is a holding company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.

D'autres rapports CampDesrEcrues

Discuter de cet article

SUIVRE NOTRE JOURNAL